Genmab (GMAB) reported worldwide net trade sales of Darzalex – daratumumab -, including sales of the subcutaneous product sold as Darzalex Faspro in the U.S., as reported by J&J (JNJ) were $3.237B in Q1. Net trade sales were $1.829B in the U.S. and $1.409B in the rest of the world. Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Advances Share Buy-back Program with Significant Transactions
- Genmab A/S Updates Articles of Association to Enhance Capital Flexibility
- Genmab Announces Share Capital Reduction Following AGM Decision
- Genmab price target lowered to $37 from $50 at H.C. Wainwright
- Genmab’s Strong Financial Performance and Strategic Positioning Justify Buy Rating Despite Minor Setbacks